research

Recently, we have seen exciting developments in the antibody-drug conjugate (ADC) space, from cloud computing to radioisotopes.

DAR is key to ADC success. Biointron explains how drug-to-antibody ratios shape potency, safety, and outcomes in cancer therapy.

The 15th World Bispecifics Summit in Boston showcased breakthroughs. Biointron shares highlights shaping the future of bispecific antibody therapeutics.

Discover how phage display technology enables high-throughput screening of antibodies, peptides, and therapeutic proteins to accelerate drug discovery and protein engineering.

Learn about dilution buffers in antibody research, their composition, and applications in ELISA, Western blotting, and immunohistochemistry for reliable results.

The 12th Immuno-Oncology Summit in Philadelphia spotlighted antibody therapeutics. Biointron shares event highlights driving progress in cancer immunotherapy.

BIX 2024 in Seoul spotlighted biotech and antibody advances. Biointron reports event highlights shaping innovation across discovery, development, and therapeutics.

Explore key highlights from PEGS 2024, featuring breakthroughs in antibody engineering, immunotherapy, ADC development, AI-driven discovery, and protein science.

Antibodies defend health by neutralizing pathogens, aiding phagocytosis, and activating complement. Biointron explains these vital functions in immunity and therapy.

The 4th Fc-Mediated Function Summit in Boston showcased Fc engineering advances. Biointron reports key insights driving next-generation antibody therapeutics.

Antibody-drug conjugates unite precision with potency. Biointron outlines how ADCs combine antibodies with cytotoxic drugs to deliver targeted cancer therapies.

AACR 2024 in San Diego spotlighted breakthroughs in cancer research. Biointron shares highlights on antibody therapeutics, discovery platforms, and translational science.

Learn about Fab, F(ab')2, and Fc antibody fragments—how they are generated, their roles in antigen targeting, and their evolving applications in biomedical research and therapy.

Explore key highlights from Biologics 2024, including advances in ADCs, AI-driven drug discovery, peptide therapeutics, and next-generation biologics innovation.

Single-chain variable fragments (scFvs) combine small size with strong binding. Biointron highlights their history, uses in diagnostics and therapy, and production expertise.